Floatz logo

Ambrisentan

Portal Hypertension

Noorik Biopharmaceuticals AGSmall moleculePhase 2Dormant
CC
42/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
27/ 100
Competitive Position
81/ 100

Competitive context

21 Active assets in the Portal Hypertension cohort.

Asset / SponsorPhaseRating
CARVEDILOL
West China Hospital
Phase 4BBB
SIMVASTATIN
Kafrelsheikh University
Phase 4BBB
PROPRANOLOL
West China Hospital
Phase 4BBB
Apixaban
Asian Institute Of Medical Sciences
Phase 4BB
Acetylsalicylic Acid
Northern Jiangsu People's Hospital
Phase 4BB

View all 50 →

Same molecule, other indications

Ambrisentan is also rated in:

pulmonary hypertensionDormant
CCC
Indicative ·
53 / 100
View asset →
cirrhosis of liverDormant
CCC
Indicative ·
52 / 100
View asset →
pulmonary hypertensionDormant
CCC
Indicative ·
49 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →